Sign In
Buy PRTG
$6.81
+0 (+0%)
At Close: Dec 02, 2025
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
08:01am, Friday, 12'th Apr 2024
WESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
08:01am, Tuesday, 26'th Mar 2024
Company generated approximately $2.8M of non-dilutive funding to extend cash runway Company generated approximately $2.8M of non-dilutive funding to extend cash runway
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
05:10pm, Wednesday, 28'th Feb 2024
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update Company focused on adenosine platform clinical development
Portage Biotech Reports Business and Strategic Update
08:00am, Thursday, 04'th Jan 2024
WESTPORT, Conn., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
04:01pm, Tuesday, 28'th Nov 2023
WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in
WESTPORT, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, to
Portage Biotech Announces $6.0 Million Registered Direct Offering
08:00am, Friday, 29'th Sep 2023
WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and
Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference
08:00am, Wednesday, 20'th Sep 2023
WESTPORT, Conn., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and
WESTPORT, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update
08:00am, Wednesday, 30'th Aug 2023
Company focused on accelerating clinical programs for PORT-2, PORT-6, and PORT-7 Company focused on accelerating clinical programs for PORT-2, PORT-6, and PORT-7
Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update
04:05pm, Monday, 31'st Jul 2023
WESTPORT, Conn., July 31, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in
New Strong Buy Stocks for January 26th
09:02am, Thursday, 26'th Jan 2023
FYBR, SPPJY, KMTUY, PRTG and ASML have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.
New Strong Buy Stocks for January 20th
07:32am, Friday, 20'th Jan 2023
NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.
New Strong Buy Stocks for November 1st
10:32am, Tuesday, 01'st Nov 2022
FFNW, PTEN, PRTG, NTNX and GAMB have been added to the Zacks Rank #1 (Strong Buy) List on November 1, 2022.
Does Portage Biotech Inc. (PRTG) Have the Potential to Rally 206% as Wall Street Analysts Expect?
11:37am, Monday, 01'st Aug 2022
The mean of analysts' price targets for Portage Biotech Inc. (PRTG) points to a 206.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
